ReviewCancers2026
Epigallocatechin-3-Gallate (EGCG) as a Multifaceted Natural Anticancer Agent in Colorectal Cancer: Preclinical Evidence and Future Directions.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) accounted for nearly 2 million new cases and over 900,000 deaths worldwide in 2020. Current treatment strategies include surgery, chemotherapy, radiotherapy, and targeted therapies, including monoclonal antibodies and other forms of immunotherapy. Despite these options, high mortality rates and frequent treatment-related adverse effects underscore the urgent need for novel therapeutic approaches. Epigallocatechin-3-gallate (EGCG), the most abundant catechin in green tea, exhibits potent antioxidant, anti-inflammatory, and anticancer activities. This review summarizes evidence from the past decade on the in vitro and in vivo effects of EGCG in CRC. In vitro studies demonstrate that EGCG inhibits cell proliferation and migration while inducing apoptosis through multiple molecular mechanisms, including modulation of signaling pathways such as Wnt/β-catenin, PI3K/Akt, and NF-κB. In vivo studies in mouse xenograft models indicate that EGCG reduces tumor growth, volume, and mass. Nevertheless, additional in vivo investigations are needed to fully define EGCG's therapeutic potential and its translational relevance for human clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.